OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Neurology is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Lymphatic propagation of α-synuclein	499
Microglia, spreaders of Aβ seeds	443
Transmembrane protein interacts with α-synuclein to confer risk of PD	299
Promising results for antisense RNA therapy in mouse models of diffuse midline glioma	288
Ventricular enlargement caused by aducanumab	285
Brain stimulation aids walking after spinal injury	267
Getting specific: targeting Fc receptors in myasthenia gravis	240
Neural cell state shifts and fate loss in ageing and age-related diseases	232
Global synergistic actions to improve brain health for human development	209
Reply to ‘Perils and pitfalls of near-death experience research’	207
Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implications	206
Refining oxytocin therapy for autism: context is key	206
Deciphering nociplastic pain: clinical features, risk factors and potential mechanisms	196
NODDI reveals brain microstructural changes in multiple sclerosis	186
Disease-specific modifications of tau protein	177
Continuous levodopa production by an artificial enzyme	176
CD11c+ macrophages mediate brain-to-gut α-synuclein trafficking	166
The impact of rare genetic variants on Alzheimer disease	164
Spinal muscular atrophy treatment in utero	161
Nir Giladi (1955–2024)	141
The Digitized Memory Clinic	138
SEQUINS — a new initiative to address disparities in neurology	134
Mitochondrial DNA instability in Huntington disease	128
Study reveals new ALS risk genes	127
TREM2 mediates phagocytosis in glioblastoma	124

Rapidly progressive dementias — leukodystrophies as a potentially treatable cause	124
Imperatives and co-benefits of research into climate change and neurological disease	121
Microglia subset associated with high-grade glioma	117
The role of the gut microbiota in multiple sclerosis	110
Maternal immune activation and neuroinflammation in human neurodevelopmental disorders	106
Ultrasound lets gene therapy into the brain	102
Brain volume is associated with cognition in MS	101
Role for endogenous retrovirus in FTD	100
Menopause influences tau pathology	98
Neurological care for LGBT+ people	97
Amyloid plaques: hotspots for microglial turnover	97
The challenges of anti-tau therapeutics in Alzheimer disease	95
Psychosis-causing lesions mapped to a hippocampal circuit	95
Neuroinflammation predicts cognitive decline in FTD	93
Implications of AD plasma and PET biomarker discordance	91
MRI-based deep learning for TLE diagnosis	90
Diversity, equity and inclusion in neurology	85
Brain imaging illuminates cognitive impairment in multiple sclerosis	85
APOE ε4 influences Parkinson disease progression	84
Author Correction: Viral pathogens increase risk of neurodegenerative disease	82
First trials test targeting of α-synuclein for Parkinson disease	82
Parkinson disease pathology can originate in the kidney	79
Precision neuroimmunology in multiple sclerosis — the horizon is near	78
Gene therapy for seizures in focal cortical dysplasia	75
Challenges of combining multimodal data in assessment of people with traumatic brain injury	74
Management of freezing of gait — mechanism-based practical recommendations	74
α-Synuclein pathology as a target in neurodegenerative diseases	74
The noradrenergic subtype of Parkinson disease: from animal models to clinical practice	71
Blood GFAP as an emerging biomarker in brain and spinal cord disorders	69
Evidence for altered astrocyte function in Duchenne muscular dystrophy	68
New IDEAS about amyloid, race and dementia disparities	67
Food is brain medicine — relevance and translation to neurology	65
Glymphatic dysfunction in PD clinical progression	64
Neurosteroids alleviate seizures in rats	64
Thalamic inflammation — a therapeutic target for brain injury?	63
A new biological classification for Parkinson disease	62
Exosomal microRNA is promising biomarker in PD	60
Addressing disparities in neurology by building the workforce in LMICs	59
Ultrasound ablation treatment for PD	56
Post-COVID dysautonomias: what we know and (mainly) what we don’t know	55
Amyloid-lowering immunotherapies for Alzheimer disease: current status and future directions	55
Coeliac disease as a model for understanding multiple sclerosis	55
Knowing the enemy: strategic targeting of complement to treat Alzheimer disease	54
Author Correction: Why won’t it stop? The dynamics of benzodiazepine resistance in status epilepticus	53
The global and regional burden of diabetic peripheral neuropathy	52
The role of glial cells in multiple sclerosis disease progression	50
From the prodromal stage of multiple sclerosis to disease prevention	48
Apparent changes in the epidemiology and severity of multiple sclerosis	48
Synaptic degeneration in Alzheimer disease	47
Spinal cord stimulation for the treatment of chronic pain	46

Why won’t it stop? The dynamics of benzodiazepine resistance in status epilepticus	44
Is Alzheimer disease a disease?	44
Oligomeric tau could spread through synapses in AD	43
Hypothalamus loses control in migraine	43
Cognitive impairment and World Trade Centre-related exposures	42
X-chromosome variants and PD in Latin America	42
Hypothyroidism is associated with dementia risk	42
Limbic-predominant age-related TDP43 encephalopathy (LATE) neuropathological change in neurodegenerative diseases	41
Continuing evolution of migraine-specific therapies — targeting migraine with precision and persistence	41
Neurofilament light chain induces neuroinflammation	40
Genetic susceptibility determines Epstein–Barr-virus-associated risk of multiple sclerosis	40
Peripheral nervous system immune-related adverse events due to checkpoint inhibition	40
Global epidemiology of migraine and its implications for public health and health policy	38
The inter-relationship between delirium and dementia: the importance of delirium prevention	37
Safety and efficacy of COVID-19 vaccines in people with neurological disorders	37
Dual function of biomolecular condensates	36
T cells implicate Epstein–Barr virus in multiple sclerosis pathogenesis	36
Risk locus for paediatric astrocytoma identified	35
Moving towards meaningful patient and public engagement	35
Impaired glymphatic drainage links amyloid and tau to cognitive dysfunction	35
New developments in guidelines for brain death/death by neurological criteria	34
α-Synuclein seeds in amyotrophic lateral sclerosis	34
Reactive astrocyte biomarkers mirror Alzheimer disease pathology	33
Multi-ancestry GWAS identifies 16 novel Alzheimer disease risk loci	33
Insights from 25 years of onabotulinumtoxinA in migraine — mechanisms and management	33
Plasma extracellular vesicle biomarkers for frontotemporal dementia and related disorders	33
Prognostic plasma biomarkers for spinal cord injury	33
The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology	32
CAR T cells offer hope in glioblastoma	32
Huntington disease-like 2: insight into neurodegeneration from an African disease	31
The role of astrocytic α7 nicotinic acetylcholine receptors in Alzheimer disease	30
The case for low-level BACE1 inhibition for the prevention of Alzheimer disease	30
Origins and immunopathogenesis of autoimmune central nervous system disorders	29
Inflammasomes in neurological disorders — mechanisms and therapeutic potential	28
Facioscapulohumeral muscular dystrophy: the road to targeted therapies	27
Positron emission tomography in multiple sclerosis — straight to the target	25
Change in stroke outcomes over 20 years	24
Antisense oligonucleotide shows potential in Charcot–Marie–Tooth disease	24
Twin study probes non-heritable immune aspects of multiple sclerosis	23
Multiple sclerosis treatment blunts SARS-CoV-2 antibody response	23
Deep learning distinguishes tauopathies	23
Neurogenesis altered in multiple neurodegenerative diseases	23
High rate of epilepsy in young individuals who died with COVID-19	21
Serum NfL as an MS biomarker	20
AI and protein structure and function in neurological disease: relevance to disease management	20
Charting brain development across the human lifespan	20
Does antiherpetic antiviral therapy reduce the risk of dementia?	20
John Q. Trojanowski	19
ALS pathogenesis linked to actin barrier collapse	18
Author Correction: The complex aetiology of cerebral palsy	17
BCAS1+ oligodendrocytes aid remyelination in MS	17
Neurological manifestations of rhino-oculo-cerebral mucormycosis in the COVID-19 era	17
Aberrant protein networks in Alzheimer disease	17
Pharmacological rehabilitation for stroke	16
Pathogenetic mechanisms and treatment targets in cerebral malaria	16
AI aces diagnosis of chronic ataxias	16
Neuroprognostication: a conceptual framework	16
Genome-wide analysis furthers decoding of Alzheimer disease genetics	15
Addressing disparities in the global epidemiology of stroke	15
Molecular biomarkers for vascular cognitive impairment and dementia	14
Alzheimer disease in African American individuals: increased incidence or not enough data?	14
Clocking the age of Parkinson disease onset	13
The murky waters of sex differences in post-stroke cognitive impairment	13
Nusinersen treatment response markers	12
Effects of diet on MS onset and course	12
Altered muscle cholesterol transport in ALS	12
Nanoprobe for blood–brain barrier changes	11
Mechanistic insights into the interaction between epilepsy and sleep	11
Addressing racial inequities in neuropsychological assessment requires international prescriptive standards, not demographically adjusted norms	11
Advancing multiple sclerosis management in older adults	11
Disease-modifying therapies for Parkinson disease: lessons from multiple sclerosis	10
Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies	10
Predictive tools in psychosis: what is ‘good enough’?	10
Alzheimer disease seen through the lens of sex and gender	10
Sex and gender in neurodevelopmental conditions	10